The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
Indianapolis, IN - A European postmarketing surveillance study of Guidant Corporation's cardiac resynchronization device for use in heart failure (HF) has shown that 60% of the 1000 patients using it ...
MINNEAPOLIS -- The novel dual-function cardiac contractility modulation-defibrillator (CCM-D) for heart failure with reduced ejection fraction (HFrEF) had favorable early results in the Integra-D ...
In today’s world we have come to rely on our devices, such as smartphones, tablets and laptops, as a key element in all aspects of our lives. Whether it’s letting loved ones know we’re on our way, ...
Wearable electronic devices such as smart watches, worn by consumers to monitor their health, could interfere with the correct working of cardiac implantable electronic devices (CIEDs), posing serious ...
DUBLIN--(BUSINESS WIRE)--The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
Results from the Cardiac Resynchronization—Heart Failure (CARE-HF) study support the use of implantable cardiac-resynchronization devices in patients with heart failure due to left-ventricular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results